AGuIX
- Generic Name
- AGuIX
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates. It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.
- Associated Conditions
- -
- Associated Therapies
- -
NH TherAguix advances Phase II brain metastases treatment trial
NH TherAguix's Phase II NANOBRAINMETS trial of AGuIX for brain metastases received DSMB validation to continue. The trial, managed by Dana Farber Cancer Institute, assesses AGuIX plus stereotactic radiotherapy versus radiotherapy alone. AGuIX showed a favorable safety profile, and 96 out of 134 planned patients have been randomised. An interim efficacy analysis is expected by year-end.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath